NCT06170190View on ClinicalTrials.gov

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions

Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions

BIOLOGICAL

IBI133

"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"

Trial Locations (1)

2170

RECRUITING

Liverpool Hospital, Liverpool

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06170190 - A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours | Biotech Hunter | Biotech Hunter